# A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

> **NCT00048152** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 539 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Corticosteroids
- **DRUG:** Neoral
- **DRUG:** Neoral
- **DRUG:** Zenapax
- **DRUG:** mycophenolate mofetil [CellCept]

## Key facts

- **NCT ID:** NCT00048152
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 539 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048152, "A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00048152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*